Effect of transcutaneous auricular vagus nerve stimulation on impaired glucose tolerance: a pilot randomized study.
Effect of transcutaneous auricular vagus nerve stimulation on impaired glucose tolerance: a pilot randomized study.
复制标题
DOI：
10.1186/1472-6882-14-203
复制
发表时间：
2014-06-26
影响因子：
--
通讯作者：
Rong P
中科院分区：
文献类型：
--
作者：
Huang F;Dong J;Kong J;Wang H;Meng H;Spaeth RB;Camhi S;Liao X;Li X;Zhai X;Li S;Zhu B;Rong P
糖耐量受损（IGT）是糖尿病前期的高血糖状态，与胰岛素抵抗、II型糖尿病风险增加和心血管病理有关。最近，研究人员假设迷走神经活动的减少可能是代谢综合征（包括肥胖、血糖水平升高和高血压）的潜在机制。在这项前瞻性随机临床试验中，我们比较了经皮耳迷走神经刺激（taVNS）和假taVNS对IGT患者的疗效。72名IGT患者采用单盲法，通过计算机生成的信封随机分配到taVNS或假taVNS治疗组。此外，招募了30名接受IGT治疗的成年人作为对照人群，不进行治疗，以监测IGT患者糖耐量的自然波动。所有治疗均由患者在医院接受培训后在家中自行进行。患者被要求每天填写一本患者日记，描述每次治疗后的任何副作用。治疗期为12周。治疗组和对照组的基线比较显示，在体重、BMI、收缩压、舒张压、空腹血糖（FPG）、2小时血糖（2hPG）或糖化血红蛋白（HbAlc）方面没有差异。100名参与者完成了这项研究，并被纳入数据分析。2例女性患者（taVNS组1例，假taVNS组1例）因刺激诱发头晕退出研究。停止治疗后症状缓解。与假taVNS相比，taVNS显著降低了大鼠2小时葡萄糖耐量（F(2) = 5.79, p = 0.004）。此外，我们发现与假taVNS相比，taVNS可显著降低收缩压（F(1) = 4.21, p = 0.044）。与未接受taVNS治疗的对照组相比，接受taVNS治疗的患者在12周治疗期间FPG （F（2) = 10.62, p < 0.001）、2hPG F(2) = 25.18, p < 0.001）和HbAlc （F(1) = 12.79, p = 0.001）的测量有显著差异。我们的研究表明，taVNS是一种有前景的、简单的、具有成本效益的治疗IGT/糖尿病前期的方法，只有轻微的副作用风险。
Impaired glucose tolerance (IGT) is a pre-diabetic state of hyperglycemia that is associated with insulin resistance, increased risk of type II diabetes, and cardiovascular pathology. Recently, investigators hypothesized that decreased vagus nerve activity may be the underlying mechanism of metabolic syndrome including obesity, elevated glucose levels, and high blood pressure. In this pilot randomized clinical trial, we compared the efficacy of transcutaneous auricular vagus nerve stimulation (taVNS) and sham taVNS on patients with IGT. 72 participants with IGT were single-blinded and were randomly allocated by computer-generated envelope to either taVNS or sham taVNS treatment groups. In addition, 30 IGT adults were recruited as a control population and not assigned treatment so as to monitor the natural fluctuation of glucose tolerance in IGT patients. All treatments were self-administered by the patients at home after training at the hospital. Patients were instructed to fill in a patient diary booklet each day to describe any side effects after each treatment. The treatment period was 12 weeks in duration. Baseline comparison between treatment and control group showed no difference in weight, BMI, or measures of systolic blood pressure, diastolic blood pressure, fasting plasma glucose (FPG), 2-hour plasma glucose (2hPG), or glycosylated hemoglobin (HbAlc). 100 participants completed the study and were included in data analysis. Two female patients (one in the taVNS group, one in the sham taVNS group) dropped out of the study due to stimulation-evoked dizziness. The symptoms were relieved after stopping treatment. Compared with sham taVNS, taVNS significantly reduced the two-hour glucose tolerance (F(2) = 5.79, p = 0.004). In addition, we found that taVNS significantly decreased (F(1) = 4.21, p = 0.044) systolic blood pressure over time compared with sham taVNS. Compared with the no-treatment control group, patients receiving taVNS significantly differed in measures of FPG (F(2) = 10.62, p < 0.001), 2hPG F(2) = 25.18, p < 0.001) and HbAlc (F(1) = 12.79, p = 0.001) over the course of the 12 week treatment period. Our study suggests that taVNS is a promising, simple, and cost-effective treatment for IGT/ pre-diabetes with only slight risk of mild side-effects.
登录
查看更多内容
影响因子：
158.5
作者：
Knowler, WC;Barrett-Connor, E;Nathan, DM
通讯作者：
Nathan, DM
影响因子：
6
作者：
De Couck, Marijke;Mravec, Boris;Gidron, Yori
通讯作者：
Gidron, Yori
影响因子：
16.2
作者：
HARRIS, MI
通讯作者：
HARRIS, MI
DOI：
10.1016/s0140-6736(12)60283-9
发表时间：
2012-06-16
期刊：
Lancet (London, England)
影响因子：
--
作者：
Tabák AG;Herder C;Rathmann W;Brunner EJ;Kivimäki M
通讯作者：
Kivimäki M
抑郁症患者的耳部经皮神经电刺激：随机对照试验研究
影响因子：
3.3
作者：
Hein, Ernst;Nowak, Magdalena;Kraus, Thomas
通讯作者：
Kraus, Thomas